Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (OTCID:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 16, 2024 5:01pm
New Press Release - Antibe Announces TSX Delisting Review
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company’s financial condition as a criterion for delisting...
read article.
(1566)
•••
Duster340
X
Post by
Duster340
on Apr 16, 2024 1:21pm
Ate is burning Nuances cash (legal fees & paychecks)🕙📜
the Company has obtained protection from its creditors for an initial period expiring April 18, 2024 (the "Stay Period"), the maximum permitted under the CCAA. At a hearing scheduled
...more
(128)
•••
MrMugsy
X
Post by
MrMugsy
on Apr 15, 2024 7:26pm
I don't know ...
I think I was right ... we should have stalled to avoid an arbitration readout. I think the way I said it was ... I think both sides should stall and avoid an arbitration readout. I stand behind
...more
(0)
•••
Gessurong
X
Comment by
Gessurong
on Apr 15, 2024 12:19am
RE:RE:FDA Concerns
mugsy 2 step: 1.mugsy assumes 2.when he's wrong he assumes something else. 3.repeat from step one
(128)
•••
MrMugsy
X
Comment by
MrMugsy
on Apr 14, 2024 10:38pm
RE:FDA Concerns
We should assume they will make us take blood samples of the trial patients. Let's hope that we don't need to - would be far better for us.
(128)
•••
MrMugsy
X
Comment by
MrMugsy
on Apr 14, 2024 10:35pm
RE:Big point is
Oh my - Looking for Clues is back as Simon. You get kicked out and then you resurface. I can tell by the way you make things up as you go. Love it !!!!
(15)
•••
SimonSaysLues
X
Post by
SimonSaysLues
on Apr 14, 2024 2:20am
Big point is
None of the science matters at this juncture. Ate owes 33 mil to Nuance. There is no appeal process. End story. Nuance is a big company. Has the best lawyers. Is found to be right by
...more
(1566)
•••
Duster340
X
Post by
Duster340
on Apr 14, 2024 12:04am
Will be interesting 🔜⤵
to see how it all plays out. and who ends up with the rights to the otena data, maybe it gets incinerated lol. one thing is for sure any current sharholders are about to be fleeced.
(17)
•••
mstrmnds
X
Post by
mstrmnds
on Apr 13, 2024 7:26pm
FDA Concerns
1) Safety Data Clarification The actual exposure based on the new Otenaproxesul formulation from the most recent PK/PD data is expected to be lower than prior conservative estimates because: 1) the
...more
(1)
•••
CalgaryATE
X
Post by
CalgaryATE
on Apr 13, 2024 3:42pm
Must Read - Extremely Detailed information on Antibe
https://www.insolvencies.deloitte.ca/en-ca/Documents/en-ca-insolv-Antibe-ApplicationRecord.pdf I'll paste this on CEO, Stockhouse and the Discord server. Feel free to post the link
...more
(15)
•••
SimonSaysLues
X
Post by
SimonSaysLues
on Apr 13, 2024 6:35am
I'm having a party...April 18 msg me if interested
Going out of business sale! There's a pony ride and the annual fleecing ceremony. Great prizes to be had. Meet and greet with Danny and his his dog Mugs. Get to know the staff
...more
(0)
•••
Gessurong
X
Comment by
Gessurong
on Apr 12, 2024 6:52pm
RE:Is an IOU ok nuance?
What did health Canada say that makes this a red flag to invest in?
(0)
•••
Gessurong
X
Post by
Gessurong
on Apr 12, 2024 6:50pm
Is an IOU ok nuance?
One such License Agreement was entered into by Antibe in February 2021 with a company called Nuance Pharma Limited ("Nuance) for the territory of the Greater China Region (the "Nuance
...more
(0)
•••
Gessurong
X
Comment by
Gessurong
on Apr 12, 2024 4:27pm
RE:From legal papers
Copy from https://www.insolvencies.deloitte.ca/en-ca/Documents/en-ca-insolv-Antibe-Endorsement-April92024.pdf
(0)
•••
Gessurong
X
Post by
Gessurong
on Apr 12, 2024 4:20pm
From legal papers
Antibe has had both ups and downs, in terms of the development and trial results for Otenaproxesul. It ran into complications in the development and approval of the Drug in September of 2021, leading
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts